Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from EZH2-dependent phenotypic plasticity reveals TTP-associated and mTORC1 therapeutic vulnerabilities in lethal prostate cancer. Local targets link to admitted publications; unresolved targets remain external evidence.
Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers
10.1158/1078-0432.ccr-15-1259 · 2016 · External reference
Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer
10.1038/nm.4045 · 2016 · External reference
Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance
10.1126/science.aah4199 · 2017 · External reference
Phenotypic Plasticity - Alternate Transcriptional Programs Driving Treatment Resistant Prostate Cancer
10.1615/critrevoncog.2022043096 · 2022 · External reference
Lineage plasticity in prostate cancer depends on JAK/STAT inflammatory signaling
10.1126/science.abn0478 · 2022 · External reference
A basal stem cell signature identifies aggressive prostate cancer phenotypes
10.1073/pnas.1518007112 · 2015 · External reference
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma
10.1038/nature03664 · 2005 · External reference
Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors
10.1126/scitranslmed.3002003 · 2011 · External reference
Reversal of viral and epigenetic HLA class I repression in Merkel cell carcinoma
10.1172/jci151666 · 2022 · External reference
Polycomb Directed Cell Fate Decisions in Development and Cancer
10.3390/epigenomes6030028 · 2022 · External reference
A bivalent chromatin structure marks key developmental genes in embryonic stem cells
10.1016/j.cell.2006.02.041 · 2006 · External reference
Acquired Tissue-Specific Promoter Bivalency Is a Basis for PRC2 Necessity in Adult Cells
10.1016/j.cell.2016.04.031 · 2016 · External reference
Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes
10.1038/s41467-024-51156-5 · 2024 · External reference
Regulation of chromatin structure by site-specific histone H3 methyltransferases
10.1038/35020506 · 2000 · External reference
A cryptic transactivation domain of EZH2 binds AR and AR's splice variant, promoting oncogene activation and tumorous transformation
10.1093/nar/gkac861 · 2022 · External reference
Targeting RET Kinase in Neuroendocrine Prostate Cancer
10.1158/1541-7786.mcr-19-1245 · 2020 · External reference
Phosphoproteome Integration Reveals Patient-Specific Networks in Prostate Cancer
10.1016/j.cell.2016.07.007 · 2016 · External reference
Ectopic JAK-STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance
10.1038/s43018-022-00431-9 · 2022 · External reference
Epigenetic regulation of autophagy by the methyltransferase EZH2 through an MTORC1-dependent pathway
10.1080/15548627.2015.1117734 · 2015 · External reference
GSK343 induces autophagy and downregulates the AKT/mTORC1 signaling pathway in pancreatic cancer cells
2019 · External reference
Ezh2 promotes mammary tumor initiation through epigenetic regulation of the Wnt and mTORC1 signaling pathways
10.1073/pnas.2303010120 · 2023 · External reference
EZH2-inhibitor DZNep enhances apoptosis of renal tubular epithelial cells in presence and absence of cisplatin
10.1186/s13008-020-00064-3 · 2020 · External reference
EZH2 cooperates with gain-of-function p53 mutants to promote cancer growth and metastasis
10.15252/embj.201899599 · 2019 · External reference
Loss of EZH2 Reprograms BCAA Metabolism to Drive Leukemic Transformation
10.1158/2159-8290.cd-19-0152 · 2019 · External reference
Single-cell analysis supports a luminal-neuroendocrine transdifferentiation in human prostate cancer
10.1038/s42003-020-01476-1 · 2020 · External reference
Single-cell analysis of mouse and human prostate reveals novel fibroblasts with specialized distribution and microenvironment interactions
10.1002/path.5751 · 2021 · External reference
A Cellular Anatomy of the Normal Adult Human Prostate and Prostatic Urethra
10.1016/j.celrep.2018.11.086 · 2018 · External reference
RNA velocity of single cells
10.1038/s41586-018-0414-6 · 2018 · External reference
A statistical framework for differential pseudotime analysis with multiple single-cell RNA-seq samples
10.1038/s41467-023-42841-y · 2023 · External reference
Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9
10.1038/nbt.3437 · 2016 · External reference
Quality control, modeling, and visualization of CRISPR screens with MAGeCK-VISPR
10.1186/s13059-015-0843-6 · 2015 · External reference
MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens
10.1186/s13059-014-0554-4 · 2014 · External reference
Endogenous purification reveals GREB1 as a key estrogen receptor regulatory factor
10.1016/j.celrep.2013.01.010 · 2013 · External reference
Defining cellular population dynamics at single-cell resolution during prostate cancer progression
10.7554/elife.79076 · 2022 · External reference
Characterization of LY3023414, a Novel PI3K/mTORC1 Dual Inhibitor Eliciting Transient Target Modulation to Impede Tumor Growth
10.1158/1535-7163.mct-15-0996 · 2016 · External reference
Interleukin-17 promotes metastasis in an immunocompetent orthotopic mouse model of prostate cancer
2018 · External reference
Patient derived organoids to model rare prostate cancer phenotypes
10.1038/s41467-018-04495-z · 2018 · External reference
Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial
10.1016/s1470-2045(20)30441-1 · 2020 · External reference
A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTORC1 Dual Inhibitor, in Patients with Advanced Cancer
10.1158/1078-0432.ccr-17-3421 · 2018 · External reference
Low tristetraprolin expression activates phenotypic plasticity and primes transition to lethal prostate cancer in mice
2024 · External reference
Protein phosphatase 2A (PP2A) is increased in old murine B cells and mediates p38 MAPK/tristetraprolin dephosphorylation and E47 mRNA instability
10.1016/j.mad.2010.02.002 · 2010 · External reference
Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets
10.1158/2159-8290.cd-11-0130 · 2011 · External reference
Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling
10.1016/j.ccell.2017.09.003 · 2017 · External reference
SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer
10.1126/science.aah4307 · 2017 · External reference
Identification of multipotent luminal progenitor cells in human prostate organoid cultures
10.1016/j.cell.2014.08.017 · 2014 · External reference
Regenerative potential of prostate luminal cells revealed by single-cell analysis
10.1126/science.aay0267 · 2020 · External reference
Adult murine prostate basal and luminal cells are self-sustained lineages that can both serve as targets for prostate cancer initiation
10.1016/j.ccr.2012.01.005 · 2012 · External reference
Intermediate cells in human prostate epithelium are enriched in proliferative inflammatory atrophy
10.1016/s0002-9440(10)64286-1 · 2003 · External reference
Prostate cancer originating in basal cells progresses to adenocarcinoma propagated by luminal-like cells
10.1073/pnas.1320565110 · 2013 · External reference
Identification of a cell of origin for human prostate cancer
10.1126/science.1189992 · 2010 · External reference
Targeting EZH2 in cancer
10.1038/nm.4036 · 2016 · External reference
Increased translation driven by non-canonical EZH2 creates a synthetic vulnerability in enzalutamide-resistant prostate cancer
10.1038/s41467-024-53874-2 · 2024 · External reference
EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent
10.1126/science.1227604 · 2012 · External reference
Context-specific regulation of NF-kappaB target gene expression by EZH2 in breast cancers
10.1016/j.molcel.2011.08.011 · 2011 · External reference
Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential
10.1186/s40364-018-0122-2 · 2018 · External reference
Combinatorial antitumor effect of HDAC and the PI3K-Akt-mTORC1 pathway inhibition in a Pten defecient model of prostate cancer
10.18632/oncotarget.1314 · 2013 · External reference
Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers
10.1158/2767-9764.crc-23-0250 · 2023 · External reference
Assessments of prostate cancer cell functions highlight differences between a pan-PI3K/mTORC1 inhibitor, gedatolisib, and single-node inhibitors of the PI3K/AKT/mTORC1 pathway
10.1002/1878-0261.13703 · 2025 · External reference
Dual targeting of the androgen receptor and PI3K/AKT/mTORC1 pathways in prostate cancer models improves antitumor efficacy and promotes cell apoptosis
10.1002/1878-0261.13577 · 2024 · External reference
Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer
10.1158/2159-8290.cd-16-1174 · 2017 · External reference
Identification of RNA-Binding Proteins as Targetable Putative Oncogenes in Neuroblastoma
10.3390/ijms21145098 · 2020 · External reference
NFIB overexpression cooperates with Rb/p53 deletion to promote small cell lung cancer
10.18632/oncotarget.11583 · 2016 · External reference
Nfib Promotes Metastasis through a Widespread Increase in Chromatin Accessibility
10.1016/j.cell.2016.05.052 · 2016 · External reference
MYBL2 Drives Prostate Cancer Plasticity: Inhibiting Its Transcriptional Target CDK2 for RB1-Deficient Neuroendocrine Prostate Cancer
10.1158/2767-9764.crc-24-0069 · 2024 · External reference
N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer
10.1016/j.ccell.2016.09.005 · 2016 · External reference
N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer
10.1172/jci127961 · 2019 · External reference
Patterns in the tapestry of chromatin-bound RB
10.1016/j.tcb.2023.07.012 · 2024 · External reference
Notch signaling suppresses neuroendocrine differentiation and alters the immune microenvironment in advanced prostate cancer
10.1172/jci175217 · 2024 · External reference
Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1
10.1073/pnas.1905384117 · 2020 · External reference
SynergyFinder 2.0: visual analytics of multi-drug combination synergies
10.1093/nar/gkaa216 · 2020 · External reference
STAR: ultrafast universal RNA-seq aligner
10.1093/bioinformatics/bts635 · 2013 · External reference
